What the Study Found (In Plain English)
Published in NEJM evidence (2026), this phase iii randomized trial evaluating 140 human participants investigated: Glucocorticoids (GCs) are standard treatment for giant cell arteritis (GCA). Key clinical takeaway: Sustained remission at week 52 did not differ significantly between patients with GCA randomly assigned to receive SEC-300 with a 26-week GC taper versus placebo with a 52-week GC taper.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (NEJM evidence, 2026-07-15; N = 140; Rigor 88/100): Sustained remission at week 52 did not differ significantly between patients with GCA randomly assigned to receive SEC-300 with a 26-week GC taper versus placebo with a 52-week GC taper.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.